Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
在歐洲藥品管理局將Pegcetacoplan的地理萎縮審查重置爲初步評估的第180天之後，Apellis Pharmicals的股價走高。
Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment.
在歐洲藥品管理局將Pegcetacoplan的地理萎縮審查重置爲初步評估的第180天之後，Apellis Pharmicals的股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。